Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 1
2009 1
2010 4
2013 2
2014 3
2016 1
2017 4
2018 1
2019 2
2020 3
2022 3
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, Harada N, Miyahara Y, Seo N, Hattori H, Takada K, Emori M, Kakunaga S, Endo M, Matsumoto Y, Sasada T, Sato E, Yamada T, Matsumine A, Nagata Y, Watanabe T, Kageyama S, Shiku H. Ishihara M, et al. Among authors: muraoka d. Int J Cancer. 2023 Jun 15;152(12):2554-2566. doi: 10.1002/ijc.34453. Epub 2023 Feb 17. Int J Cancer. 2023. PMID: 36727538 Clinical Trial.
Single-cell sequencing on CD8+ TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer/testis antigen in non-small cell lung cancer.
Komuro H, Shinohara S, Fukushima Y, Demachi-Okamura A, Muraoka D, Masago K, Matsui T, Sugita Y, Takahashi Y, Nishida R, Takashima C, Ohki T, Shigematsu Y, Watanabe F, Adachi K, Fukuyama T, Hamana H, Kishi H, Miura D, Tanaka Y, Onoue K, Onoguchi K, Yamashita Y, Stratford R, Clancy T, Yamaguchi R, Kuroda H, Doi K, Iwata H, Matsushita H. Komuro H, et al. Among authors: muraoka d. J Immunother Cancer. 2023 Aug;11(8):e007180. doi: 10.1136/jitc-2023-007180. J Immunother Cancer. 2023. PMID: 37544663 Free PMC article.
New evaluation of the tumor immune microenvironment of non-small cell lung cancer and its association with prognosis.
Shinohara S, Takahashi Y, Komuro H, Matsui T, Sugita Y, Demachi-Okamura A, Muraoka D, Takahara H, Nakada T, Sakakura N, Masago K, Miyai M, Nishida R, Shomura S, Shigematsu Y, Hatooka S, Sasano H, Watanabe F, Adachi K, Fujinaga K, Kaneda S, Takao M, Ohtsuka T, Yamaguchi R, Kuroda H, Matsushita H. Shinohara S, et al. Among authors: muraoka d. J Immunother Cancer. 2022 Apr;10(4):e003765. doi: 10.1136/jitc-2021-003765. J Immunother Cancer. 2022. PMID: 35396225 Free PMC article.
Inhibition of STAT3 by Anticancer Drug Bendamustine.
Iwamoto K, Uehara Y, Inoue Y, Taguchi K, Muraoka D, Ogo N, Matsuno K, Asai A. Iwamoto K, et al. Among authors: muraoka d. PLoS One. 2017 Jan 26;12(1):e0170709. doi: 10.1371/journal.pone.0170709. eCollection 2017. PLoS One. 2017. PMID: 28125678 Free PMC article.
Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance.
Muraoka D, Seo N, Hayashi T, Tahara Y, Fujii K, Tawara I, Miyahara Y, Okamori K, Yagita H, Imoto S, Yamaguchi R, Komura M, Miyano S, Goto M, Sawada SI, Asai A, Ikeda H, Akiyoshi K, Harada N, Shiku H. Muraoka D, et al. J Clin Invest. 2019 Mar 1;129(3):1278-1294. doi: 10.1172/JCI97642. Epub 2019 Feb 11. J Clin Invest. 2019. PMID: 30628894 Free PMC article.
30 results